Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 12/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.46 |
| ▸ | CTSD | P07339 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8579953 | 0.97 | NAALAD2 (0.47) | NAALAD2BACE1BACE2CTSDMMP1 | |
| SCHEMBL30533108 | 0.94 | BACE1 (0.55) | BACE1BACE2CTSD | |
| SCHEMBL30659882 | 0.93 | BACE1 (0.57) | BACE1BACE2CTSD | |
| SCHEMBL31453841 | 0.93 | DPP4 (0.39) | NAALAD2BACE1BACE2CTSD | |
| SCHEMBL30575178 | 0.92 | NAALAD2 (0.51) | NAALAD2BACE1BACE2 | |
| SCHEMBL30692727 | 0.91 | MME (0.47) | — | |
| SCHEMBL30578424 | 0.91 | MME (0.47) | — | |
| SCHEMBL31259942 | 0.91 | MME (0.47) | — | |
| SCHEMBL29577210 | 0.91 | MME (0.47) | — | |
| SCHEMBL17768459 | 0.91 | DPP4 (0.40) | NAALAD2BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515617-A | Diamine-linked receptor-specific cyclic peptides | 帕拉丁科技公司 | 2022-12-23 | — | — | CN | disclosed |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | PALATIN TECHNOLOGIES, INC. (US) | 2022-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | MC3R, MC1R, MC2R | NAALAD2 1790/4885BACE1 1862/4885BACE2 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.